Research Article

Analytical Variables Affecting Analysis of F₂-Isoprostanes and F₄-Neuroprostanes in Human Cerebrospinal Fluid by Gas Chromatography/Mass Spectrometry

Hsiu-Chuan Yen, Hsing-Ju Wei, and Ting-Wei Chen

Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Tao-Yuan 333, Taiwan

Correspondence should be addressed to Hsiu-Chuan Yen; yen@mail.cgu.edu.tw
Received 19 February 2013; Accepted 13 May 2013

Academic Editor: Shih-Bin Su

Copyright © 2013 Hsiu-Chuan Yen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

F₂-isoprostanes (F₂-IsoPs) are a gold marker of lipid peroxidation in vivo, whereas F₄-neuroprostanes (F₄-NPs) measured in cerebrospinal fluid (CSF) or brain tissue selectively indicate neuronal oxidative damage. Gas chromatography/negative-ion chemical-ionization mass spectrometry (GC/NICI-MS) is the most sensitive and robust method for quantifying these compounds, which is essential for CSF samples because abundance of these compounds in CSF is very low. The present study revealed potential interferences on the analysis of F₂-IsoPs and F₄-NPs in CSF by GC/NICI-MS due to the use of improper analytical methods that have been employed in the literature. First, simultaneous quantification of F₂-IsoPs and F₄-NPs in CSF samples processed for F₄-NPs analysis could cause poor chromatographic separation and falsely higher F₂-IsoP values for CSF samples with high levels of F₂-IsoPs and F₄-NPs. Second, retention of unknown substances in GC columns from CSF samples during F₄-NPs analysis and from plasma samples during F₂-IsoPs analysis might interfere with F₄-NPs analysis of subsequent runs, which could be solved by holding columns at a high temperature for a period of time after data acquisition. Therefore, these special issues should be taken into consideration when performing analysis of F₂-IsoPs and F₄-NPs in CSF to avoid misleading results.

1. Introduction

Reliable assessment of oxidative stress in vivo has been important for investigating the roles of oxidative stress in the pathogenesis or progression of diseases [1]. F₂-isoprostanes (F₂-IsoPs) are prostaglandin (PG)-like compounds derived from lipid peroxidation of arachidonic acid (AA, C20:4 ω-6), which is abundant in all kinds of cells, initiated by free radicals independent of the cyclooxygenase pathway. They are initially formed as esterified form on phospholipids and can be released into surrounding body fluids to become free form via the action of enzymes with the phospholipase-like activities [2–5]. There are four regioisomers of F₂-IsoPs, but the 5-series and 15-series regioisomers are the major regioisomers formed in vivo [6]. F₂-IsoPs have been well recognized as the most reliable and specific marker of lipid peroxidation in vivo and is a widely used marker of oxidative damage due to several favorable characteristics [7]. On the other hand, F₄-neuroprostanes (F₄-NPs) are generated from the lipid peroxidation of docosahexaenoic acid (DHA, C22:6 ω-3) via similar mechanisms, but eight regioisomers are produced [8]. As shown by Yin et al., 4-series and 20-series regioisomers are the most abundant regioisomers of F₄-NPs generated in vitro and in vivo [9]. Measurement of F₄-NPs in CSF or brain tissue has been considered as a more selective marker for neuronal oxidative damage because DHA is enriched in neurons [10].

Gas chromatography/negative-ion chemical-ionization mass spectrometry (GC/NICI-MS) is the most sensitive and robust method for routine quantification of F₂-IsoPs and F₄-NPs in biological samples [11, 12], which is required for body fluids with low levels of free F₂-IsoPs and F₄-NPs or limited availability, such as cerebrospinal fluid (CSF). Different assay platforms and further modifications for GC/NICI-MS analysis of F₂-IsoPs and F₄-NPs were present in the literature as discussed in our previous paper [13], but most...
of the them were modified from procedures from the groups of Roberts or Morrow [8, 14, 15]. As previously reviewed by us, methods involving liquid chromatography/mass spectrometry (LC/MS) were superior than the GC/NICI-MS method primarily in the aspect of identification of different regioisomers, but it could only be used for quantification of highly abundant free \( F_2 \)-IsoPs in urine or total levels of \( F_2 \)-IsoPs in plasma, which consisted of abundant esterified \( F_2 \)-IsoPs from lipoproteins, due to its lower sensitivity [16]. Moreover, the unique lipid chromatographic/atmospheric pressure chemical ionization mass spectrometry (LC/APCI-MS) method developed by Yin et al. was only used to identify different regioisomers of \( F_2 \)-NPs in liver tissue and DHA oxidized \textit{in vitro} [9], whereas detection of \( F_2 \)-IsoPs and \( F_4 \)-NP in CSF in the literature so far, including our studies, was only performed by the GC/NICI-MS method [8, 13, 17–21].

Although the GC/NICI-MS method has been recognized as the reference method to quantify \( F_2 \)-IsoPs and \( F_2 \)-NP levels in body fluids, several variants of analytical settings exist in the literature for GC/MS analysis. For example, the area on silica recovered from thin-layer chromatography (TLC) plates should be smaller for \( F_2 \)-IsoPs analysis than that for \( F_2 \)-NPs analysis to obtain better chromatographic separation [13, 17], but Corcoran et al. simultaneously analyze total (free plus esterified) levels of \( F_2 \)-IsoPs, \( F_4 \)-NPs, and isofurans, another product of lipid peroxidation from AA, in human CSF without showing any chromatogram when they employed a very different method without the step of TLC purification [18]. Because the amount of CSF needed for \( F_4 \)-NPs is much higher for \( F_2 \)-IsoPs analysis, it is also a tempting idea to perform simultaneous analysis of the same sample when the amount of CSF samples available is very little. On the other hand, during our previous investigation on \( F_4 \)-NPs of human CSF, we noticed obvious retention of unknown compounds from the previous samples on GC columns at m/z 593.5, which was used to detect \( F_4 \)-NPs, by using the temperature ramp commonly indicated to analyze \( F_2 \)-IsoPs or \( F_2 \)-NPs [15, 22]. We speculated that when this problem was not noticed, the results of \( F_4 \)-NPs quantification in CSF might not be reliable. Accordingly, we also wondered whether analysis of \( F_4 \)-NPs in CSF could also be affected by the retention effect following analysis of \( F_2 \)-IsoPs of CSF or other body fluids since it was very common to analyze different samples for either \( F_2 \)-IsoPs or \( F_4 \)-NPs interchangeably during routine operation.

In this report, we first investigated whether simultaneous analysis of \( F_2 \)-IsoPs and \( F_4 \)-NPs for CSF samples processed for \( F_4 \)-NPs analysis is feasible by comparing chromatograms and results of \( F_2 \)-IsoPs quantification from CSF samples processed for \( F_2 \)-IsoPs and \( F_4 \)-NPs separately. Furthermore, we systematically examined whether significant amount of substances was retained in GC columns from previously injected samples by simultaneously recording chromatograms at m/z 569.4, m/z 593.5, and m/z 573.4, which were masses employed to detect \( F_2 \)-IsoPs, \( F_4 \)-NPs, and \( [\text{H}_2] \)-15-\( F_2 \)\(-\text{IsoP} \) (internal standard), respectively, after analyzing \( F_2 \)-IsoPs and \( F_4 \)-NPs in CSF or analyzing \( F_2 \)-IsoPs in urine and plasma. We also evaluated whether the peaks from the retained substances could overlap with the peaks for quantification of \( F_2 \)-IsoPs, \( F_4 \)-NPs, or \( [\text{H}_2] \)-15-\( F_2 \)\(-\text{IsoP} \) (internal standard) at their corresponding masses. Finally, the beneficial effect of additional holding of the column at a high temperature after regular data acquisition in the method setting on removing retained peaks was investigated.

2. Materials and Methods

2.1. Test Samples. For the testing in this study, we used three pooled human CSF samples with different levels of \( F_2 \)-IsoPs and \( F_4 \)-NPs, which were designated as L-CSF, M-CSF, and H-CSF for low levels, medium levels, and high levels of these compounds, respectively. L-CSF sample was from patients with normal pressure hydrocephalus, whereas M-CSF and H-CSF samples were from patients with aneurysmal subarachnoid hemorrhage (aSAH). These CSF samples were pooled from specimen collected during our previous study on aSAH that have been published [13, 17], in which we showed that CSF samples from aSAH had much higher levels of \( F_4 \)-NPs than that from non-aSAH controls including those with normal pressure hydrocephalus [13]. Moreover, one test plasma sample and one test urine sample were also pooled samples from normal subjects used in the previous studies [23].

2.2. Sample Processing and GC/MS Detection for Analysis of Free \( F_2 \)-IsoPs in CSF, Plasma, and Urine. The methods of analyzing free \( F_2 \)-IsoPs in human body fluids was modified from the procedures described by the Morrow's group [11, 14]. Some of major modifications on solid-phase extraction (SPE) and GC/MS settings have been indicated in our previous publications [13, 17]. In brief, an appropriate volume of body fluids was added into 3 mL of ultrapure water containing the internal standards and the pH was adjusted to pH 3, which was followed by two runs of SPE purification with C18 columns and then silica columns. The internal standard used for CSF and plasma was \( [\text{H}_2] \)-15-\( F_2 \)-IsoP [14], whereas that used for urine was \( [\text{H}_4] \)-8-\( F_4 \)-IsoP to avoid interferences peaks from endogenous substances in urine samples [24]. \( [\text{H}_4] \)-15-\( F_2 \)-IsoP and \( [\text{H}_4] \)-8-\( F_4 \)-IsoP were purchased from Cayman Chemical, which were designated as 8-iso prostaglandin \( F_2\alpha \)-\( d_4 \) (catalog number 316350) and \( iPF_2\alpha \)-1V-\( d_1 \) (catalog number 316230), respectively, in the catalog of Cayman Chemical. These organic solvents in vials containing the two internal standards purchased from Cayman Chemical were evaporated and resuspended in a fixed amount of ethanol followed by the calibration of true concentration of the internal standard in the ethanol solution by the method of Milne et al. [11]. In this study, 0.6 mL of CSF, 0.5 mL of plasma, and 0.05 mL of urine samples were mixed with 100 pg, 250 pg, and 330 pg of the internal standards, respectively, for each sample preparation. Because the concentrations of M-CSF and H-CSF samples were known to be much higher than L-CSF, only 0.4 mL and 0.24 mL of M-CSF and H-CSF samples, respectively, were used along with 0.6 mL of L-CSF for the test described in this study.
2.3. Sample Processing and GC/MS Detection for Analysis of Free F₂-NPs in CSF. The procedures for analysis of free F₂-NPs in human CSF have been described previously in our publication [13], which were modified from the method of Arneson and Roberts II [15], except that 250 pg of the internal standard [²H₄]-15-F₂-Isop was used with 1.5 mL of CSF. For M-CSF and H-CSF, 1 mL and 0.6 mL of samples, respectively, were used and diluted to 1.5 mL with water before adding into 3 mL of water. The whole process and principle are similar to those for analysis of free F₂-Isops in body fluids. One difference was that the washing solvent for silica SPE columns in the second SPE was ethyl acetate [14] and ethyl acetate/heptane (75:25) [15] for F₂-Isops analysis and F₄-NPs, respectively. Another difference was that the scraping area of TLC plates for extraction of F₂-NPs was 1 cm below and 3 cm above the TLC standard [8, 13] instead of the 2 cm range performed for F₂-Isops analysis described in Section 2.2. Different from other methods described in the literature, we previously established the method by overlaying the chromatograms of CSF samples with that of products from in vitro oxidation of DHA at m/z 593.5 to identify the range of peaks for quantification of F₂-NPs [13, 16]. In this study, as for the F₂-Isops analysis, additional 2-min run at 300°C was included for the acquisition of chromatograms. The setting of additional 30-min holding at 280°C without turning the detector on was included in the method for our routine analysis, which was based on the observation from this study, was purposely omitted for some tests in this report.

Amount of F₂-NPs in samples was quantified by multiplying amount of [²H₄]-15-F₂-Isop added into samples with the ratio of the peak area of F₂-NPs at m/z 593.5, which was defined by the range of peaks of oxidized DHA, to that of [²H₄]-15-F₂-Isop.

2.4. Statistical Analysis. The significance of the difference for the data between the 2 groups was evaluated using a two-tailed independent t-test with SPSS software (SPSS Inc.). The Levene test was also conducted to determine whether p values should be obtained under the assumption of equal variance or unequal variance. Statistical significance was considered when p values were smaller than 0.05.

3. Results

3.1. Results of F₂-Isops Analysis in CSF for Samples Processed for F₂-Isops versus Samples Processed for F₄-NPs. To address the question that whether simultaneous analysis of F₂-Isops and F₄-NPs for the same CSF sample processed for F₂-NPs analysis was appropriate, we first analyzed F₂-Isops and F₄-NPs simultaneously for L-CSF, M-CSF, and H-CSF samples processed for F₄-NPs analysis from three independent replicates of each sample. The results of F₂-Isops quantification were then compared with those for the corresponding three CSF samples processed for F₂-Isops analysis in a separate experiment. As shown by Table 1, we found that differences in mean values of F₂-Isops from samples processed in two different ways relative to the values from samples processed for F₂-Isops were small for L-CSF (5.2%) and M-CSF (1.7%) but were very high for H-CSF (66%). Despite of having the small difference for values of F₂-Isops quantified from two different methods (5.2%), there was statistical significance between values of F₂-Isops for L-CSF processed for F₂-Isops analysis versus for F₄-NPs analysis. It could be a systematic difference due to amount of CSF samples or internal standards used in two different operations. On the other hand, due to wider TLC scraping ranges for F₂-NPs analysis, the abundance of the peaks adjacent to the peak of F₂-Isops became much higher for all samples tested. The chromatograms at m/z 569.4 of H-CSF processed in two different ways are shown to illustrate such alteration (Figure 1). The results showed that the peak resolution for samples processed for F₄-NPs was worse due to significant overlap with the adjacent peaks and...
the baseline was higher for the peak of \( F_2 \)-IsoPs compared with that processed for \( F_2 \)-IsoPs.

3.2. Evaluation on the Extent of Sample Retention on GC Columns without Additional Holding of the Column at the High Temperature after Analysis of \( F_2 \)-NPs for the M-CSF Sample. For GC/MS settings, all methods that originated from the groups of Morrow and Roberts in the literature for \( F_2 \)-IsoPs and \( F_2 \)-NPs indicated the temperature ramp of 190 to 290 or 300 °C with additional holding [11, 12, 14, 15]. However, during the analysis of \( F_2 \)-NPs in human CSF for our previous study on aSAH [13], we noticed that some residual substances on the GC column after each analysis tended to be retained and eluted out together with the next samples, which could be detected at \( m/z \) 593.5, although the degree of this effect varied from sample to sample. To more systematically examine such effect at different masses, in this study, we performed right after analysis of \( F_2 \)-IsoPs may be performed right after analysis of \( F_2 \)-NPs during routine operation.

All the sources and processing of samples were the same for different figures for this test. Only M-CSF was used for this purpose. To simulate the method frequently applied, second holding of the GC column at 280°C with the detector off was not conducted although we included 2-min holding at 300°C at the end of temperature ramp to make the acquisition of chromatograms more complete. As shown by Figure 2, chromatograms in the range of 3.6 min to 8.6 min (the end of data acquisition) of the 4 undecane washes after the injection of M-CSF sample indicated that there were obvious unknown peaks retained in the column from the previous CSF sample at \( m/z \) 573.4 and \( m/z \) 593.5 but not \( m/z \) 569.4. Some peaks of washes were at the retention time for the quantification of target compounds, such as one peak of Wash-2 at \( m/z \) 573.4 and three peaks of Wash-1 at \( m/z \) 593.5, although the abundance of the peaks from these washes was much less than that from the CSF sample. Moreover, the peak \( a \) of Wash-1 at \( m/z \) 573.4 and the peak \( b \) of Wash-2 at \( m/z \) 593.5 were very large although they did not overlap with the retention time of \( F_2 \)-NPs peaks.

Furthermore, we wondered how the chromatograms would look like and the degree of retention would be when 5 CSF samples were analyzed consecutively without additional holding. To examine this issue, multiple processed M-CSF samples dissolved in undecane were pooled together and multiple injections from the same pooled sample were performed. We found that the large peaks, peak \( a \) and peak \( b \), at \( m/z \) 573.4 and \( m/z \) 593.5, respectively, showed up behind the target peaks during the injections of real samples, which were similar to the pattern found in Figure 2 (middle and right panels of Figure 3). Moreover, small but obvious peaks at the retention time for the quantification of target peaks also appeared in Wash-2 at \( m/z \) 573.4 and 4 Washes at \( m/z \) 593.5 (middle and right panels of Figure 3). On the contrary, there was no obvious obscure peak beyond background signals in the chromatograms at \( m/z \) 569.4 (left panel of Figure 3).

3.3. Evaluation on the Extent of Sample Retention on GC Columns without Additional Holding of the Column at the High Temperature after Analysis of \( F_2 \)-IsoPs for the M-CSF, Plasma, and Urine Samples. The same pattern of examination described in Section 3.2 was also applied to M-CSF, plasma, and urine samples processed for \( F_2 \)-IsoPs analysis. The chromatograms of 5 consecutive sample injections from the same pooled sample dissolved in undecane and 4 undecane washes were monitored. Although \( m/z \) 593.5 was not used for analysis of \( F_2 \)-IsoPs, any retained compounds detectable at \( m/z \) 593.5 might interfere with the analysis of \( F_2 \)-NPs of the next samples. The amount of M-CSF, plasma, and urine samples indicated in Section 2 was used and processed as for our routine analysis of \( F_2 \)-IsoPs. The chromatograms at \( m/z \) 569.4 in a short range of retention time showed that we had proper analysis of \( F_2 \)-IsoPs for those samples by our routine analysis (Figure 4(a)). The comparison on chromatograms in the range of 4.4 min to 8.6 min (the end of data acquisition) at \( m/z \) 593.5 for this test on CSF, plasma, and urine is shown by Figure 4(b), in which that for Wash-4 is not shown because of low abundance. Because the amount of the CSF sample processed for \( F_2 \)-IsoPs analysis was less than that for \( F_2 \)-NPs and the scanning area for TLC purification was also smaller, the abundance of peaks at \( m/z \) 593.5 was much smaller, but there was also a relatively large peak (peak \( c \)) at the end of chromatograms of Sample-3 to Sample-5 and Wash-1 to Wash-2 (left panel of Figure 4(b)) similar to those observed during \( F_2 \)-NPs analysis (Figure 3). Interestingly, a group of the retained peaks (\( d \) peaks) in the range of retention time for \( F_2 \)-NPs quantification or the large peak (peak \( e \)) at the end of chromatograms rises markedly for Sample-3 to Sample-5 and remained in high abundance for Wash-1 and Wash-2 (middle panel of Figure 4(b)). On the contrary, there was no apparent peak from retained substances in the chromatograms of the samples and there were only minimal signals in the chromatograms of Wash-1 and Wash-2 for urine samples (right panel of Figure 4(b)). Moreover, chromatograms of all samples and washes at \( m/z \) 569.4 had no obvious retention effect (see Supplemental Figure 1 of the Supplementary Material available online at http://dx.doi.org/10.1155/2013/810915), while only some peaks with low abundance showed up in Wash-1 and Wash-2 after injections of plasma samples at \( m/z \) 573.4 (Supplemental Figure 2). Because the amount of internal standard monitored at \( m/z \) 573.4 was very large, such low-abundant residual peaks should not affect the quantification of the internal standard.

3.4. Chromatograms Monitored during the Second Holding of the Column after Normal Acquisition of Data. Next, we monitored possible presence of peaks in the chromatograms at all three masses representing residual substances from the first injection of samples during additional holding of the column at 280°C for 30 min after normal acquisition of data. When the same processed CSF sample used in Figure 2 was analyzed for \( F_2 \)-NPs, there was no peak with appreciable
amount of abundance at m/z 569.4 during this second holding time (upper panel of Figure 5(a)), but significant amount of residual substances could be detected at m/z 573.4 and 593.5 (middle and lower panels of Figure 5(a)). Moreover, based on the patterns of the surrounding peaks, peak a and peak b indicated in Figures 2 or 3 might be present during this second holding and then moved to the retention time in the range of data acquisition during next runs.

The chromatograms during the second holding were also monitored for the same processed CSF, plasma, and urine samples used in Figure 4. The results showed that many peaks in substantial amount could be detected for plasma samples, whereas small but obvious peaks from the CSF and urine samples were also detectable during the additional 30-min holding at 280°C (Figure 5(b)). Peaks that were likely to be peak c, d peaks, and peak e were also found on the chromatograms. Moreover, there was no obvious signal above background signals at m/z 569.4 for CSF, plasma, and urine samples (Supplemental Figure 3(a)). The abundance of the retained peaks in the chromatograms at m/z 573.4 was also very low (Supplemental Figure 3(b)).

3.5. Demonstration on the Elimination of Retention Effect by Additional Holding of GC Columns at a High Temperature at the End of Each Sample Analysis. To avoid potential interferences of the retention effect on the subsequent analysis of F₄-NPs in CSF at m/z 593.5, we previously needed to conduct multiple injections of undecane to monitor the conditions of GC columns, which was a troublesome process. To eliminate this problem during sample analysis in a more efficient way, we have incorporated additional holding of the column recommended by the manufacturer, into the method for each injection without the detector on, which could reduce contamination of the ion source. The holding time was determined by the degree of improvement on removing retained peaks, which was confirmed by the absence of obvious peaks in the subsequent washes and disappearance of retained peaks during the second holding as what monitored in Figure 5 and in this section.

To demonstrate the effectiveness of such modification on the method setting, chromatograms for the F₄-NPs quantification of the 5 consecutive CSF samples without and with the additional 30-min holding were compared (Figure 6). The left panel of Figure 6 is the same as the right panel of Figure 3 except showing a narrower range of retention time, which focuses on peaks for F₄-NPs quantification. The results indicated that the patterns of F₄-NPs peaks were gradually altered and the baseline of the peaks gradually elevated from CSF-1 through CSF-5 when there was no additional holding after acquisition of chromatograms (left panel of Figure 6). However, such interference was not found when the additional holding was conducted (right panel of Figure 6). Moreover, the large peak b at the end of chromatograms (right panel of Figure 3) and other small interfering peaks in the range of the retention time (left panel of Figure 6) for F₄-NPs quantification in the chromatograms at m/z 593.5 of the subsequent 4 undecane washes could be observed after the CSF analysis when additional holding was not performed. That disappeared after additional 30-min holding was included in the method (right panel of Figure 6 and right panel of Supplemental Figure 4). Although there were some visible peaks in the chromatogram of Wash-2 even with additional holding, the abundance was too low to affect the quantification. On the other hand, the peak a and other small
Figure 2: Chromatograms at m/z 569.4, m/z 573.4, and m/z 593.5 for the M-CSF sample processed for F\textsubscript{2}-NPs analysis and the 4 subsequent injections of undecane alone (Wash-1 to Wash-4). The chromatograms in the range of 3.6 min to 8.6 min (the end of data acquisition) were compared. The peak of F\textsubscript{2}-IsoPs is indicated by the arrow. The peak of [\textsuperscript{4}H\textsubscript{4}] F\textsubscript{2}-IsoPs is indicated by the asterisk. Peak a and peak b indicated in the text were peaks of the retained substances from the sample with very high abundance. The range of retention time for quantification of F\textsubscript{2}-NPs peaks at m/z 593.5, which is defined by that for the peaks of oxidized DHA, is indicated by the brace.

Table 1: Results of quantification of F\textsubscript{2}-IsoPs and F\textsubscript{4}-NPs in three test CSF samples that have been processed for F\textsubscript{2}-IsoPs (IsoP method) or F\textsubscript{4}-NPs (NP method) analysis.

|                  | NP method | IsoP method | % of difference for F\textsubscript{2}-IsoPs $^c$ |
|------------------|-----------|-------------|-----------------------------------------------|
|                  | F\textsubscript{2}-NPs (pg/mL) | F\textsubscript{2}-IsoPs (pg/mL) | F\textsubscript{2}-IsoPs (pg/mL) |
| L-CSF            | 57.7 ± 5.1 (8.8%)   | 19.5 ± 0.1 (0.5%)   | 20.6 ± 0.4 (1.7%) $^a$   |
| M-CSF            | 109.0 ± 9.9 (9.1%)  | 56.9 ± 1.7 (3.0%)   | 55.9 ± 0.9 (1.7%)   |
| H-CSF            | 1023.4 ± 116.7 (11.4%)  | 141.0 ± 4.0 (2.8%)  | 85.0 ± 0.8 (0.9%) $^b$   |

There were three replicates for each CSF sample. Nine CSF samples were processed and analyzed together. Data were presented as mean ± standard deviation (coefficient of variation). Coefficient of variation was the ratio of standard deviation to mean presented as percentage and was used to represent within-run imprecision. $^a p < 0.05$ (p = 0.007 under assumption of equal variance versus values of F\textsubscript{2}-IsoPs for L-CSF processed by the NP method). $^b p < 0.05$ (p = 0.001 under assumption of unequal variance versus values of F\textsubscript{2}-IsoPs for H-CSF processed by the NP method). $^c$ The difference between the mean values of two methods divided by the mean values from IsoP method is calculated and represented as % of difference.

peaks during runs of CSF samples or washes at m/z 573.4 (middle panel of Figure 3) also disappeared (left panel of Supplemental Figure 4).

The quantification results of CSF-1 to CSF-5 in Figure 6 are listed in Table 2. The trend of increase in the latter injections of samples without additional holding was clear. The quantification results were significantly greater and the within-run imprecision, presented as coefficient of variation, was higher when samples were analyzed without additional holding than that with additional holding (Table 2). In contrast, the method without the additional holding did not result in significantly higher values of F\textsubscript{2}-IsoPs in CSF when the same test was performed on the CSF sample processed for F\textsubscript{2}-IsoPs analysis (Table 3).

Furthermore, the comparison on the chromatograms in the absence and presence of second holding of the column
Figure 3: Chromatograms at m/z 569.4, m/z 573.4, and m/z 593.5 for the 5 consecutive injections of the same pooled M-CSF sample processed for F4-NPs analysis (CSF-1 to CSF-5) and the 4 subsequent injections of undecane alone (Wash-1 to Wash-4). The chromatograms in the range of 3.6 min to 8.6 min (the end of data acquisition) were compared. The peaks of F2-IsoPs at m/z 569.4 are indicated by the arrows. The peaks of [2H4]-15-F2-IsoP at m/z 573.4 are indicated by the asterisks. The range of retention time for quantification of F4-NPs peaks at m/z 593.5, which is defined by that for the peaks of oxidized DHA, is indicated by the brace.
Figure 4: (a) Chromatograms at m/z 569.4 in a narrower range of retention time for the same pooled M-CSF sample, the plasma sample, and the urine sample processed for F₂-IsoPs analysis. The peaks of F₂-IsoPs are indicated by asterisks. The concentrations of F₂-IsoPs quantified by the routine operation described in Section 2 were 54.9 pg/mL, 13.5 pg/mL, and 851 pg/mL for the CSF sample, the plasma sample, and the urine sample, respectively. (b) Chromatograms for the 5 consecutive injections of the same M-CSF sample (left panel), the same plasma sample (middle panel), and the same urine sample (right panel) processed for F₂-IsoPs analysis (Sample-1 to Sample-5) and the 3 subsequent injections of undecane alone (Wash-1 to Wash-3) at m/z 593.5. The chromatograms in the range of 4.4 min to 8.6 min (the end of data acquisition) were compared. The range of retention time corresponding to that for F₄-NPs quantification is indicated by the braces although these samples were not used for F₄-NPs quantification.
Table 2: Results of quantification of F4-NPs from 5 consecutive injections of the same pooled sample.

|          | F4-NPs levels (pg/mL) |          | F4-NPs levels (pg/mL) |
|----------|-----------------------|----------|-----------------------|
|          | No additional holding | 30-min holding | No additional holding | 30-min holding |
| CSF-1    | 119.9                 | 113.8    | CSF-1                | 56.1          | 54.8         |
| CSF-2    | 130.2                 | 114.0    | CSF-2                | 55.5          | 55.3         |
| CSF-3    | 144.4                 | 117.7    | CSF-3                | 54.8          | 55.2         |
| CSF-4    | 145.5                 | 119.3    | CSF-4                | 54.1          | 56.4         |
| CSF-5    | 147.5                 | 121.7    | CSF-5                | 53.8          | 55.5         |
| Mean ± SD| 137.5 ± 12.0          | 117.3 ± 3.4* | Mean ± SD            | 54.9 ± 1.0    | 55.4 ± 0.6   |
| (CV%)    | (8.7%)                | (2.9%)   | (CV%)                | (1.8%)        | (1.1%)       |

The sample number was designated according to the sequence of injection. The quantification data for samples analyzed without additional holding corresponds to chromatograms shown by the left panel of Figure 6, whereas that with 30-min holding corresponds to chromatograms shown by the right panel of Figure 6. CV is coefficient of variation that is the ratio of standard deviation (SD) to mean. *p < 0.05 (p = 0.017 under assumption of equal variance).

Table 3: Results of quantification of F2-IsoPs from 5 consecutive injections of the same pooled sample.

|          | F2-IsoPs levels (pg/mL) |          | F2-IsoPs levels (pg/mL) |
|----------|-------------------------|----------|-------------------------|
|          | No additional holding   | 30-min holding | No additional holding   | 30-min holding |
| CSF-1    | 56.1                    | 54.8     | CSF-1                | 56.1          | 54.8         |
| CSF-2    | 55.5                    | 55.3     | CSF-2                | 54.8          | 55.2         |
| CSF-3    | 54.8                    | 55.2     | CSF-3                | 54.1          | 56.4         |
| CSF-4    | 54.1                    | 56.4     | CSF-4                | 53.8          | 55.5         |
| CSF-5    | 53.8                    | 55.5     | CSF-5                | 53.8          | 55.5         |
| Mean ± SD| 54.9 ± 1.0              | 55.4 ± 0.6 | Mean ± SD            | 54.9 ± 1.0    | 55.4 ± 0.6   |
| (CV%)    | (1.8%)                  | (1.1%)   | (CV%)                | (1.8%)        | (1.1%)       |

The sample number was designated according to the sequence of injection. There was no statistical significance between two sets of data obtained by two different methods (p = 0.281 under assumption of equal variance).

Because chromatograms of urine samples did not exhibit any appreciable amount of peaks from retained substances that may further affect subsequences analysis of next samples at all three masses detected (Figure 4, Supplemental Figures 1,
Figure 6: Comparison on the chromatograms for the 5 consecutive injections of the same pooled M-CSF sample processed for F$_4$-NPs analysis (CSF-1 to CSF-5) at m/z 593.5 without (left panel) and with (right panel) additional 30-min holding of the column at 280$^\circ$C at the end of data acquisition. For better viewing of the peaks of F$_4$-NPs and the adjacent peaks, the chromatograms in the range of 4.8 min to 7.8 min were compared. The peaks for F$_4$-NPs quantification are indicated by the braces.
Figure 7: Comparison on the chromatograms at m/z 593.5 for one CSF sample (a) or one plasma sample (b) processed for F$_4$-IsoPs analysis that has been used in Figure 4 without (left panel) and with (right panel) additional 30-min holding of the column at 280°C at the end of data acquisition. The range of retention time corresponding to that for F$_4$-NPs quantification is indicated by the braces although these samples were not used for F$_4$-NPs quantification.
that analyzed F42 for F4 marker [16, 25]. Although quite a few of studies have detected F42-IsoPs in human CSF, such as our study on aSAH [17] and several publications on Alzheimer’s disease (AD) [19, 21, 26], so far only three groups have measured F44-NPs in human CSF, which included the original report of Roberts et al. on AD [8], our studies on aSAH [13] and traumatic brain injury (TBI) [27], and the studies of Corcoran et al. on aSAH and TBI [18]. However, variations in analytical protocols and further modifications for the GC/NICI-MS analysis of these compounds without description of methods in detail or the demonstration on chromatographic data with acceptable resolution of peaks may lead to questionable results.

In this study, we demonstrated that simultaneous analysis of F42-IsoPs and F44-NPs for the human CSF samples processed for F44-NPs analysis caused much more overlap of the peak for F42-IsoPs and the adjacent peaks at m/z 569.4 compared with the sample that was processed for F42-IsoPs analysis. Consequently, the quantification results of F42-IsoPs became inaccurate and unreliable if CSF samples had very high levels of F42-IsoPs and F44-NPs. This indicates that proper TLC purification is critical to avoid the interferences on quantification of F42-IsoPs from substances with retention time that overlapped with the retention time of F42-IsoPs, such as other related lipid peroxidation products, PGs, and their metabolites. These compounds may not be all removed by SPE. In the literature, few studies simply quantified F42-IsoPs and F44-NPs simultaneously for brain tissues processed by the same TLC purification when using the methods of Milatovic et al. [28], Milne et al. [29], or Zhang et al. [30]. This practice may be avoided because brain tissues contain much higher amount of these compounds than CSF samples, but it might be followed for CSF samples because the availability of CSF samples is usually very limited. Great care therefore should be taken. Furthermore, although we did not perform methods described by Nourooz-Zadeh et al. [31] or Corcoran et al. [18] that analyzed F42-IsoPs and F44-NPs simultaneously for human brain tissue [31] or human CSF [18] using different methods without the step of TLC purification, the same concern raised by us should also be applied to these two platforms.

The results from this study also revealed for the first time that significant amount of unknown compounds with low volatility were retained in the GC column from human CSF and plasma sample processed for either F42-IsoPs or F44-NPs analysis by using the regular GC elution method that originated from the methods established by the group of Roberts or Morrow [8, 11, 12, 14, 15]. Urine samples did not cause much retention effect based on the observation from the current examination possibly because we routinely started with a much less amount of urine than what was indicated in the literature. However, we cannot exclude the possibility that this phenomenon could also be enhanced by greater loading amount of samples into the GC columns even with urine samples. Although the residual substances at m/z 573.4 theoretically would not affect quantification of the internal standard because of the presence of relatively large amount of the internal standard, it was important to note that unknown substances at m/z 573.4 were also retained in the GC column substantially from CSF samples during F44-NPs analysis. Furthermore, many of major peaks detected during the additional holding time shown in Figure 5 appeared to show up as those peaks of the undecane washes shown in Figures 2 and 3 at the end of chromatograms or in the range of retention time for F44-NPs quantification. These peaks from retained substances therefore tended to move to the earlier retention time in the subsequent injections.

The quantification of F44-NPs at m/z 593.5 for human CSF was more prone to be interfered by the retention effect from residual substances in the previous samples. When a proper method was not applied to avoid such effect, continuous injections of samples could enhance this problem by the accumulation of those substances in the GC column and enhancement of background signals. As demonstrated by our examinations, although the abundance of the interfering peaks eluted out by the undecane washes following one injection of the sample from human CSF was less than that of F44-NPs peaks at m/z 593.5 and was not likely to have a major effect on quantification of F44-NPs for the next sample (Figure 2), consecutive 5 injections of the same sample for F44-NPs quantification in the CSF sample enhanced the baseline and caused falsely higher values of F44-NPs (Figure 6 and Table 2), which could be prevented by the additional holding time at 280°C after normal acquisition of chromatographic data. In other words, the interfering effect from the retained substances could not be predicted by simply observing the chromatograms of undecane injections after a single sample injection. Although we did not test the potential interference on F44-NPs quantification in CSF following 5 consecutive analyses of plasma samples processed for F44-NPs analysis, we suspected that a group of unknown peaks (d peaks) in high abundance at m/z 593.5 from the retention of the previous plasma sample with the retention time in the range of that for F44-NPs peaks (Figure 4), which was much greater for those peaks from retention of the previous CSF sample processed for F44-NPs analysis in the same range (Figure 2), were highly likely to interfere with subsequent quantification of F44-NPs in CSF as well. Because this retention effect did not interfere with F42-IsoPs analysis at m/z 569.4 for CSF plasma, or urine samples, it would not have been noticed by most researchers who only measured F42-IsoPs levels in human body fluids. However, this problem would be a major problem when both F42-IsoPs analysis and F44-NPs analysis were carried out interchangeably on the same GC/MS equipment without performing the additional holding at 280°C.

The time needed for the second holding of the column at the high temperature varied for different analysis and should be evaluated by observing the traces of chromatograms during the long holding after the regular acquisition of
data, by comparing signals in undecane washes after sample injections with and without additional holding, and by comparing results of quantification with and without holding after multiple sample injections. The holding time therefore should also be different for different labs with different GC/MS settings or different format in sample processing, but our current study has demonstrated the rationale and necessity of such evaluation.

Taken together, this work has indicated the importance of proper TLC purification for obtaining reliable chromatograms for F$_2$-IsoPs quantification in CSF and revealed the necessity of adding additional holding of the column at 280°C for a period of time following data acquisition during F$_2$-IsoPs and F$_4$-NPs analysis to avoid potential interferences on subsequent F$_2$-NPs quantification in CSF. Although GC/NICI-MS is not a commonly used technique and is hard to manage, the GC/NICI-MS method remains to be the most sensitive and robust method for detecting F$_2$-IsoPs or F$_4$-NPs in body fluids. Many seemingly minor variations in analytical methods that may have a major impact on the reliability of results should therefore be carefully evaluated.

Acknowledgment

This work was supported by Grants NSC96-2320-B-182-018 and NSC97-2320-B-182-012-MY3 from the National Science Council, Taiwan to Hsiu-Chuan Yen.

References

[1] B. Halliwell and M. C. Gutteridge, Free Radicals in Biology and Medicine, Oxford University Press, New York, NY, USA, 2007.

[2] L. J. Roberts II and J. D. Morrow, “The generation and actions of isoprostanes,” Biochimica et Biophysica Acta, vol. 1345, no. 2, pp. 121–135, 1997.

[3] D. M. Stafforini, J. R. Sheller, T. S. Blackwell et al., “Release of free F$_2$-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases,” Journal of Biological Chemistry, vol. 281, no. 8, pp. 4616–4623, 2006.

[4] U. Jahn, J.-M. Galano, and T. Durand, “Beyond prostaglandins—chemistry and biology of cyclic oxygenated metabolites formed by free-radical pathways from polyunsaturated fatty acids,” Angewandte Chemie, vol. 47, no. 32, pp. 5894–5955, 2008.

[5] G. L. Milne, H. Yin, K. D. Hardy, S. S. Davies, and L. J. Roberts, “Isoprostane generation and function,” Chemical Reviews, vol. 111, no. 10, pp. 5973–5996, 2011.

[6] G. L. Milne, H. Yin, and J. D. Morrow, “Human biochemistry of the isoprostane pathway,” Journal of Biological Chemistry, vol. 283, no. 23, pp. 15533–15537, 2008.

[7] L. J. Roberts II and J. D. Morrow, “Measurement of F$_2$-isoprostanes as an index of oxidative stress in vivo,” Free Radical Biology and Medicine, vol. 28, no. 4, pp. 505–513, 2000.

[8] L. J. Roberts II, T. J. Montine, W. R. Markesbery et al., “Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid,” Journal of Biological Chemistry, vol. 273, no. 22, pp. 13605–13612, 1998.

[9] H. Yin, E. S. Musiek, L. Gao, N. A. Porter, and J. D. Morrow, “Regiochemistry of neuroprostanes generated from the peroxidation of docosahexaenoic acid in vitro and in vivo,” Journal of Biological Chemistry, vol. 280, no. 28, pp. 26600–26611, 2005.

[10] K. S. Montine, J. F. Quinn, J. Zhang et al., “Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases,” Chemistry and Physics of Lipids, vol. 128, no. 1-2, pp. 117–124, 2004.

[11] G. L. Milne, S. C. Sanchez, E. S. Musiek, and J. D. Morrow, “Quantification of F$_2$-isoprostanes as a biomarker of oxidative stress,” Nature Protocols, vol. 2, no. 1, pp. 221–226, 2007.

[12] W. Liu, J. D. Morrow, and H. Yin, “Quantification of F$_2$-isoprostanes as a reliable index of oxidative stress in vivo using gas chromatography-mass spectrometry (GC-MS) method,” Free Radical Biology and Medicine, vol. 47, no. 8, pp. 1101–1107, 2009.

[13] Y. P. Hsieh, C. L. Lin, A. L. Shiue et al., “Correlation of F$_2$-neuroprostanes levels in cerebrospinal fluid with outcome of aneurysmal subarachnoid hemorrhage in humans,” Free Radical Biology and Medicine, vol. 47, no. 6, pp. 814–824, 2009.

[14] G. L. Milne, H. Yin, J. D. Brooks, S. Sanchez, L. Jackson Roberts II, and J. D. Morrow, “Quantification of F$_2$-isoprostanes in biological fluids and tissues as a measure of oxidant stress,” Methods in Enzymology, vol. 433, pp. 113–126, 2007.

[15] K. O. Arneson and L. J. Roberts II, “Measurement of products of docosahexaenoic acid peroxidation, neuroprostanes, and neurofurans,” Methods in Enzymology, vol. 433, pp. 127–143, 2007.

[16] H. C. Yen, “Detection of F$_2$-isoprostanes and F$_4$-neuroprostanes in clinical studies,” Journal of Biomedical Laboratory Science, vol. 22, no. 1, pp. 1–10, 2010.

[17] C. L. Lin, Y. T. Hsu, T. K. Lin et al., “Increased levels of F$_2$-isoprostanes following aneurysmal subarachnoid hemorrhage in humans,” Free Radical Biology and Medicine, vol. 40, no. 8, pp. 1466–1473, 2006.

[18] T. B. Corcoran, E. Mas, A. E. Barden et al., “Are isofurans and neuroprostanes increased after subarachnoid hemorrhage and traumatic brain injury?” Antioxidants and Redox Signaling, vol. 15, no. 10, pp. 2663–2667, 2011.

[19] T. J. Montine, J. Quinn, J. Kaye, and J. D. Morrow, “F$_2$-isoprostanes as biomarkers of late-onset Alzheimer’s disease,” Journal of Molecular Neuroscience, vol. 33, no. 1, pp. 114–119, 2007.

[20] T. J. Montine, M. F. Beal, D. Robertson et al., “Cerebrospinal fluid F$_2$-isoprostanes are elevated in Huntington’s disease,” Neurology, vol. 52, no. 5, pp. 1104–1105, 1999.

[21] M. J. De Leon, L. Mosconi, J. Li et al., “Longitudinal CSF isoprostane and MRI atrophy in the progression to AD,” Journal of Neurology, vol. 254, no. 12, pp. 1666–1675, 2007.

[22] G. L. Milne, B. Gao, E. S. Terry, W. E. Zackert, and S. C. Sanchez, “Measurement of F$_2$-isoprostanes and isofurans using gas chromatography-mass spectrometry,” Free Radical Biology & Medicine, vol. 59, pp. 36–44, 2013.

[23] H. C. Yen, H. S. Cheng, Y. T. Hsu, H. J. Ho, C. Y. Nien, and Y. S. Lee, “Effects of age and health status on levels of urinary 15-F$_2$t-isoprostane,” Journal of Biomedical Laboratory Science, vol. 13, pp. 24–28, 2001.

[24] E. Mas, A. Barden, T. Durand, J.-M. Galano, K. D. Croft, and T. A. Mori, “Measurement of urinary F$_2$-isoprostanes by gas chromatography-mass spectrometry is confounded by interfering substances,” Free Radical Research, vol. 44, no. 2, pp. 191–198, 2010.
[25] S. Basu, "F₂-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications," Antioxidants and Redox Signaling, vol. 10, no. 8, pp. 1405–1434, 2008.

[26] T. J. Montine, M. F. Beal, M. E. Cudkowicz et al., "Increased CSF F₂-isoprostane concentration in probable AD," Neurology, vol. 52, no. 3, pp. 562–565, 1999.

[27] T. W. Chen, C. L. Lin, and H. C. Yen, "Elevation of F₂-isoprostanes and F₄-neuroprostanes levels in cerebrospinal fluid of patients with traumatic brain injury," Free Radical Biology & Medicine, vol. 47, Abstract S108, 2009.

[28] D. Milatovic, M. VanRollins, K. Li, K. S. Montine, and T. J. Montine, "Suppression of murine cerebral F₂-isoprostanes and F₄-neuroprostanes from excitotoxicity and innate immune response in vivo by α- or γ-tocopherol," Journal of Chromatography B, vol. 827, no. 1, pp. 88–93, 2005.

[29] G. L. Milne, J. D. Morrow, and M. J. Picklo Sr., "Elevated oxidation of docosahexaenoic acid, 22:6 (n-3), in brain regions of rats undergoing ethanol withdrawal," Neuroscience Letters, vol. 405, no. 3, pp. 172–174, 2006.

[30] Y. Zhang, D. Milatovic, M. Aschner, P. J. Feustel, and H. K. Kimelberg, "Neuroprotection by tamoxifen in focal cerebral ischemia is not mediated by an agonist action at estrogen receptors but is associated with antioxidant activity," Experimental Neurology, vol. 204, no. 2, pp. 819–827, 2007.

[31] J. Nourooz-Zadeh, E. H. C. Liu, B. Yhlen, E. E. Änggård, and B. Halliwell, "F₂-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer’s disease," Journal of Neurochemistry, vol. 72, no. 2, pp. 734–740, 1999.